Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2022-08-10 Regulatory Filings
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled as an announcement regarding an update on an Investigational New Drug (IND) application from MaaT Pharma to the U.S. FDA concerning their drug candidate MaaT013. It discusses clinical trial status, regulatory feedback (clinical hold), and future interaction plans with the FDA. The text is formatted as a 'PRESS RELEASE' and details operational and regulatory developments rather than providing comprehensive financial statements (like 10-K or IR) or management compensation details (DEF 14A). Since it is a specific operational/regulatory update that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for non-standard regulatory communications, or potentially a Legal/Regulatory update (LTR), but RNS is more appropriate for general operational/regulatory news releases that aren't strictly legal proceedings. Given the context of an IND update, RNS is the most suitable general regulatory announcement code.
2022-08-10 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital" and explicitly references French regulatory articles (AMF General Regulations, French Commercial Code) requiring the publication of the total number of shares and voting rights on a specific date (July 31, 2022). This type of periodic disclosure detailing the capital structure and voting power is a specific regulatory requirement. While it is a regulatory filing, the most specific category that covers announcements related to share capital structure and voting rights, especially when not tied to a specific transaction (like POS or SHA), is often best categorized under general regulatory disclosures or specific capital structure updates. However, none of the provided codes perfectly match a 'Total Voting Rights' announcement. Given the content focuses purely on the count of shares and voting rights, it is a mandatory disclosure related to the company's capital structure. Since 'SHA' is for Share Issue/Capital Change (which this isn't, it's a report *of* the current state) and 'POS' is for transactions in own shares, the closest fit among the options that deals with share counts/rights is either a general Regulatory Filing (RNS) or, if we interpret the data as a fundamental component of capital reporting, it might be considered a specialized report. Since it is a mandatory, periodic disclosure of share capital structure mandated by regulators, and it is not a standard 10-K, IR, or ER, it falls best under the general regulatory announcement category (RNS) or potentially a specific capital-related code if one existed. Given the options, RNS (Regulatory Filings - general fallback) is appropriate for mandatory, non-standard disclosures. Alternatively, since it deals with the total number of shares, SHA (Share Issue/Capital Change) might be considered, but this document reports the *current state*, not an *action* of issuing/changing. I will classify it as RNS as it is a mandatory regulatory disclosure that doesn't fit the other specific financial report types.
2022-08-01 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of July 31, 2022. This type of mandatory periodic disclosure regarding the capital structure and voting rights is a specific regulatory filing, but it does not fit neatly into the primary categories like 10-K, ER, or IR. It is a notification about the share capital structure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it relates directly to the capital structure, although 'RNS' (Regulatory Filings) is a strong fallback. Given the specific nature of reporting total shares and voting rights, which is often a standalone regulatory requirement, 'SHA' is selected as the most descriptive category for a capital structure update, even if it's not a new issue, as it reports the current state of the share base.
2022-08-01 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Earnings Release Classification · 98% confidence The document is titled "MaaT Pharma Reports Cash and Revenues for Second Quarter 2022" and contains key financial highlights (cash position, revenues) and operational updates for a specific fiscal period (Q2 2022). This structure—providing key financial metrics immediately followed by operational details and outlook—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it focuses on highlights rather than full financial statements, and it is not a transcript (CT) or a presentation (IP). It is a press release announcing period results. Q2 2022
2022-07-28 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Earnings Release Classification · 98% confidence The document is titled "MaaT Pharma publie sa position de trésorerie et son chiffre d'affaires pour le second trimestre 2022" (MaaT Pharma publishes its cash position and revenue for the second quarter of 2022). It provides key financial highlights (cash position, revenue) and operational updates for a specific period (Q2 2022). This structure—announcing key financial metrics for a recent period without being the full, comprehensive annual filing (10-K) or a detailed management discussion (MDA)—strongly suggests an Earnings Release (ER). It is not a full Interim Report (IR) as it focuses on highlights and cash/revenue, not a full set of financial statements, and it is not a Call Transcript (CT) or Investor Presentation (IP). Since it is an initial announcement of period results, ER is the most appropriate classification. Q2 2022
2022-07-28 French
Terms of availability of a registration document or its updates
Report Publication Announcement Classification · 99% confidence The document is a press release titled "MaaT Pharma Announces the Availability of the 2021 Universal Registration Document". It explicitly states that the Universal Registration Document (URD) for FY2021 has been filed with the AMF and is now available to the public on the company's website and the AMF website. The document itself is short (3213 characters) and its primary function is to announce the publication/availability of a larger regulatory document (the URD), rather than being the URD itself. According to Rule #2, when a document announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). The URD is a comprehensive annual filing, but this text is the announcement of its release.
2022-07-06 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.